Our Locations

Media Office
For meetings and deliveries:
12 Veterans Square
1st Floor Left
Media, PA 19063 U.S.A.

Click here for maps and directions to us in realspace.

Postal Address
P.O. Box 209
Swarthmore, PA 19081-0209 U.S.A.

Phone: (610) 892-9942
Twitter: @TechLaw_Elman and @ElmanTechNews
eFax: (925) 226-4995

Contact Us
Send a written message. Note: there is no attorney-client relationship without a signed Letter of Engagement.

Your Name:
Your Email:
Your Location (City/State):
Phone (optional):

Please enter the text shown above:

Your Message:

Elman on Tech News via Twitter
Retaggr-enabled site

Oct. 20, 2014 – Meet Steve Zeman and get tips about European Patent Office practice

Join us Monday, October 20, 2014,  for a presentation at noon by European Patent Attorney Steve Zeman, of the Grünecker firm in Munich.

Steven M. Zeman, Ph.D.

Steven M. Zeman, Ph.D.

We look forward to learning from Steve’s extensive experience with the European Patent Office in seeking to overcome “new matter” objections and other particular difficulties.

Though educated primarily in the United States, Steve is licensed as a German and European Patent Attorney and as a European Trademark Attorney.  He holds degrees in chemistry and biochemistry from the University of California at San Diego and from Yale (Ph.D. 1999).

This meeting is co-sponsored by Elman Technology Law and Bob Yarbrough’s Delaware County Pennsylvania Intellectual Property Forum.  Pennsylvania CLE credit will be available for existing and new members of the Forum.   Participation is free of charge, but preregistration is required.  Call 610-892-9942 for further information or to register .

Venue: the Delaware County Bar Association headquarters, 335 W. Front Street, Media, PA 19063, basement conference room.  You’re welcome to bring a “brown bag” lunch.

Supreme Court, snowed by ACLU smear campaign, resurrects archaic requirement of “invention” as a test of patent eligibility.

In their decision June 13, 2013, in Association for Molecular Pathology v. Myriad Genetics, the Supreme Court seems to have been snowed by an anti-patent publicity campaign engineered by a brilliant but diabolical law professor and gullible lawyers at the venerable ACLU.

The opinion of the Court resurrects an archaic requirement of “invention” that was disavowed by Congress in 1952. The late Judge Giles S. Rich, father of the patent statute revision enacted at that time, may no longer rest in peace. See his article: Laying the Ghost of the “Invention” Requirement, 1 AIPLA Q.J. 26-45 (1972), recently reprinted in 41 AIPLA Q.J. 1-28 (2013) with a foreword by Judge Paul R. Michel.  The reprinted article is available online (AIPLA member login required).

And yet, the Court’s Myriad Genetics opinion written by Mr. Justice Thomas states:

The [patentable] Chakrabarty bacterium was new “with markedly different characteristics from any found in nature,” … due to the additional plasmids and resultant “capacity for degrading oil.” …. In this case, by contrast, Myriad did not create anything. To be sure, it found an important and useful gene, but separating that gene from its surrounding genetic material is not an act of invention [emphasis added]. Groundbreaking, innovative, or even brilliant discovery does not by itself satisfy the §101 inquiry [as to subject matter patent-eligibility].

In Biotechnology Law Report, we’ve chronicled the efforts of anti-intellectual-property activists such as Prof. Ravicher and Jeremy Rifkin to dismantle the U.S. patent system. See the article on Getting Beyond the ACLU and Public Patent Foundation’s Anti-Gene-Patent Grandstanding that I coauthored with Scott Rylan Powell in February 2010.

By hoodwinking the Supreme Court to focus on the “information content” rather than the chemical structure of the polynucleotide described in pertinent patent claims, the ACLU attorneys representing the putative plaintiffs in this case have, unwittingly or hypocritically, endorsed a philosophical worldview of “intelligent design.” Ironically, the ACLU had successfully challenged that unscientific perspective in Dover, Pennsylvania, just a 7 1/2 years ago. See my previous musings on this point.

See also Chris Holman’s Editorial in Biotechnology Law Report

For further explanation and cogent comment, see the Editorial by Prof. Chris Holman posted online at the website of Biotechnology Law Report June 26, 2013.

State of Vermont Declares War on “Patent Trolls”

Senator Patrick Leahy (D-VT) spearheaded the Leahy-Smith America Invents Act, which was signed into law on September 16, 2011, and took effect in stages culminating March 16, 2013.  During the pendency of the legislation, Sen. Leahy pointed out the long history of innovation by Vermonters, observing that Vermont receives more patents per capita than any other state in the nation.

But last week, Vermonters’ focus on patents shifted from obtaining patent protection for their innovations to avoiding burdensome claims of patent infringement, and from the seat of federal government in Washington, D.C. to the state capital of Montpelier.

State Attorney General Sues Patent Owner That Demands Licenses from End-Users of Info Tech Invention

On May 22, Attorney General William H. Sorrell announced that his office had brought a first-of-its-kind lawsuit against MPHJ Technology Investments, LLC (“MPHJ”), marking the first time that a state attorney general has filed suit against a so-called “patent troll.”

The Attorney General’s complaint filed in Vermont Superior Court alleges that MPHJ (and 40 “shell subsidiary” companies with names that look like they were spooned from a bowl of alphabet soup) has engaged in unfair and deceptive acts under Vermont’s Consumer Protection Act.  MPHJ has sought to assert certain patents against a variety of businesses by sending letters to many Vermont small businesses as part of a nationwide campaign offering licenses under the patents. The letters are said to contain multiple deceptive statements and demand about $1,000 per employee.

The complaint alleges that the following were illegal under the Vermont statute, as unfair trade practices in commerce:

  • Stating that litigation would be brought against the recipients, when MPHJ was neither prepared  nor likely to bring litigation;
  • Using legal counsel to imply that MPHJ had performed a sufficient pre-suit investigation, including investigation into the target businesses and their potentially infringing activities, that would be required to justify filing a lawsuit;
  • Targeting small businesses that were unlikely to have the resources to fight patent-litigation, or even to pay patent counsel;
  • Sending letters that threatened patent-infringement litigation with no independent evidence that the recipients were infringing its patents;
  • Shifting the entire burden of the pre-suit investigation onto the small businesses that received the letters;
  • Propounding burdensome information demands on any business that claimed not to infringe the patents;
  • Using shell corporations in  order to hide the true owners of the patents, avoid liability, and encourage quick settlements; and
  • Making deceptive statements in threatening letters which would likely lead recipients to believe the following:
    1. MPHJ would sue the target businesses if they did not respond within two weeks;
    2. MPHJ would sue the target businesses if they did not pay money;
    3. MPHJ had a reasonable basis for identifying the target businesses as infringing its patents;
    4. Subsidiary Shell LLCs were exclusive licensees able to enforce the patents;
    5. Target businesses were within the sending Shell LLC’s alleged area of exclusivity;
    6. MPHJ’s licensing program had received a positive response from the business community;
    7. Many or most businesses were interested in promptly purchasing a license from MPHJ;
    8. Based on prior licensing agreements, the fair price of a license was between $900 and $1200 per employee;
    9. Target businesses were receiving a third letter, which refers to two prior letters, when in many cases recipients had received no prior letters.

The patents referred to in the sample letter attached to the complaint are US 7,986,426; US 7,477,410; US 6,771,381; and US 6,185,590. A pending patent application is also identified in the letter, Serial No. 13/182,857, with a statement that it is expected to issue soon.  (I checked the online docket of the U.S. Patent and Trademark Office and found that the application apparently was voluntarily withdrawn from issue a few months ago to permit additional prior art to be placed before the Examiner, then formally allowed again last Monday, May 20.)  These patents are a family stemming from a provisional U.S. patent application filed in 1998 by Illinois inventor Laurence C. Klein on aspects of distributed computer architecture and “virtual copying.”

Sample claims from the more recent patents are:

Claim 1 of US 7,986,426:

A computer data management system including at least one of an electronic image, graphics and document management system capable of transmitting at least one of an electronic image, electronic graphics and electronic document to a plurality of external destinations including one or more of external devices and applications responsively connectable to at least one of locally and via Internet, comprising:

at least one scanner, digital copier or other multifunction peripheral capable of rendering at least one of said electronic image, electronic graphics and electronic document;

at least one memory storing a plurality of interface protocols for interfacing and communicating;

at least one processor responsively connectable to said at least one memory, and implementing the plurality of interface protocols as a software application for interfacing and communicating with the plurality of external destinations including the one or more of the external devices and applications,

wherein the computer data management system includes integration of at least one of said electronic image, electronic graphics and electronic document using software so that said electronic image, electronic graphics and electronic document gets seamlessly replicated and transmitted to at least one of said plurality of external destinations.

Claim 8 of US 7,477,410:

A computer data management system including at least one of an electronic image, graphics and document management system capable of transmitting at least one of an electronic image, electronic graphics and electronic document to a plurality of external destinations including one or more of external devices and applications responsively connectable at least one of locally and via the Internet, comprising:

at least one memory storing a plurality of interface protocols for interfacing and communicating;

at least one processor responsively connectable to said at least one memory, and implementing the plurality of interface protocols as a software application for interfacing and communicating with the plurality of external destinations including the one or more of the external devices and applications,

wherein the computer data management system includes the capability to integrate the electronic images into a destination application without the need to modify the destination application.

The Attorney General’s suit doesn’t allege that any of the patents is invalid, but says that a previous assignee of the patents had settled litigation by withdrawing suits without an adjudication of validity of any of the patents.   I’ve found that in the past couple of years, the patents were being similarly asserted against alleged infringers by a company called Project Paperless, LLC.  An Atlanta-based company Blue Wave Computing announced last August that they had stood up in court against Project Paperless, whereupon the patent holder withdrew the suit unconditionally.

Thus although the statutory presumption of validity expressed in the federal patent statute would continue to apply t0 these patents, the complaint seems to imply that this history is an indication of their weakness.

More to the point seems to be the allegation that MPHJ Technology, after acquiring this family of patents from a previous assignee, sent flurries of letters threatening suit on the patents but hasn’t actually sued anyone nor even hired counsel in Vermont to prepare for such litigation.  Also, the complaint accuses MPHJ Technology of failing to do their own “due diligence” investigation as to whether the recipients of the letters are in fact infringing any of the claims.   The sample letters attached to the complaint, however, seem to be an informal version of  “discovery” requests,  asking for factual responses in the form of checklists.  Whether it’s an “unfair trade practice” in Vermont for a patent holder to communicate this way with businesses that it deems are likely to be infringers is a question raised by this suit.

Vermont Enacts Prohibition Against “Bad Faith” Assertions of Patent Infringement

In addition, the Vermont legislature has just passed an amendment to the state Consumer Protection Act, which was signed into law, also on May 22. It provides certain remedies to Vermonters accused in bad faith of patent infringement. As this provision is not scheduled to take effect until July 1 this year, the Attorney General’s lawsuit against MPHJ Technology Investments, LLC, alleges violation of the preexisting version of the Act.

Here is the new provision of Vermont law:

Sec. 6. 9 V.S.A. chapter 120 is added to read:



(a) The General Assembly finds that:
(1) Vermont is striving to build an entrepreneurial and knowledge based
economy. Attracting and nurturing small and medium sized internet
technology (“IT”) and other knowledge based companies is an important part
of this effort and will be beneficial to Vermont’s future.
(2) Patents are essential to encouraging innovation, especially in the IT
and knowledge based fields. The protections afforded by the federal patent
system create an incentive to invest in research and innovation, which spurs
economic growth. Patent holders have every right to enforce their patents
when they are infringed, and patent enforcement litigation is necessary to
protect intellectual property.
(3) The General Assembly does not wish to interfere with the good faith
enforcement of patents or good faith patent litigation. The General Assembly
also recognizes that Vermont is preempted from passing any law that conflicts
with federal patent law.
(4) Patent litigation can be technical, complex, and expensive. The
expense of patent litigation, which may cost hundreds of thousands of dollars
or more, can be a significant burden on small and medium sized companies.
Vermont wishes to help its businesses avoid these costs by encouraging the
most efficient resolution of patent infringement claims without conflicting with
federal law.
(5) In order for Vermont companies to be able to respond promptly and
efficiently to patent infringement assertions against them, it is necessary that
they receive specific information regarding how their product, service, or
technology may have infringed the patent at issue. Receiving such information
at an early stage will facilitate the resolution of claims and lessen the burden
of potential litigation on Vermont companies.
(6) Abusive patent litigation, and especially the assertion of bad faith
infringement claims, can harm Vermont companies. A business that receives
a letter asserting such claims faces the threat of expensive and protracted
litigation and may feel that it has no choice but to settle and to pay a licensing
fee, even if the claim is meritless. This is especially so for small and medium
sized companies and nonprofits that lack the resources to investigate and
defend themselves against infringement claims.
(7) Not only do bad faith patent infringement claims impose a
significant burden on individual Vermont businesses, they also undermine
Vermont’s efforts to attract and nurture small and medium sized IT and other
knowledge based companies. Funds used to avoid the threat of bad faith
litigation are no longer available to invest, produce new products, expand, or
hire new workers, thereby harming Vermont’s economy.

(b) Through this narrowly focused act, the General Assembly seeks to
facilitate the efficient and prompt resolution of patent infringement claims,
protect Vermont businesses from abusive and bad faith assertions of patent
infringement, and build Vermont’s economy, while at the same time respecting
federal law and being careful to not interfere with legitimate patent
enforcement actions.

In this chapter:
(1) “Demand letter” means a letter, e-mail, or other communication
asserting or claiming that the target has engaged in patent infringement.
(2) “Target” means a Vermont person:
(A) who has received a demand letter or against whom an assertion
or allegation of patent infringement has been made;
(B) who has been threatened with litigation or against whom a
lawsuit has been filed alleging patent infringement; or
(C) whose customers have received a demand letter asserting that the
person’s product, service, or technology has infringed a patent.

(a) A person shall not make a bad faith assertion of patent infringement.

(b) A court may consider the following factors as evidence that a person
has made a bad faith assertion of patent infringement:
(1) The demand letter does not contain the following information:
(A) the patent number;
(B) the name and address of the patent owner or owners and
assignee or assignees, if any; and
(C) factual allegations concerning the specific areas in which the
target’s products, services, and technology infringe the patent or are covered
by the claims in the patent.
(2) Prior to sending the demand letter, the person fails to conduct an
analysis comparing the claims in the patent to the target’s products, services,
and technology, or such an analysis was done but does not identify specific
areas in which the products, services, and technology are covered by the
claims in the patent.
(3) The demand letter lacks the information described in subdivision (1)
of this subsection, the target requests the information, and the person fails to
provide the information within a reasonable period of time.
(4) The demand letter demands payment of a license fee or response
within an unreasonably short period of time.
(5) The person offers to license the patent for an amount that is not
based on a reasonable estimate of the value of the license.
(6) The claim or assertion of patent infringement is meritless, and the
person knew, or should have known, that the claim or assertion is meritless.
(7) The claim or assertion of patent infringement is deceptive.
(8) The person or its subsidiaries or affiliates have previously filed or
threatened to file one or more lawsuits based on the same or similar claim of
patent infringement and:
(A) those threats or lawsuits lacked the information described in
subdivision (1) of this subsection; or
(B) the person attempted to enforce the claim of patent infringement
in litigation and a court found the claim to be meritless.
(9) Any other factor the court finds relevant.

(c) A court may consider the following factors as evidence that a person
has not made a bad faith assertion of patent infringement:
(1) The demand letter contains the information described in subdivision
(b)(1) of this section.
(2) Where the demand letter lacks the information described in
subdivision (b)(1) of this section and the target requests the information, the
person provides the information within a reasonable period of time.
(3) The person engages in a good faith effort to establish that the target
has infringed the patent and to negotiate an appropriate remedy.
(4) The person makes a substantial investment in the use of the patent or
in the production or sale of a product or item covered by the patent.
(5) The person is:
(A) the inventor or joint inventor of the patent or, in the case of a
patent filed by and awarded to an assignee of the original inventor or joint
inventor, is the original assignee; or
(B) an institution of higher education or a technology transfer
organization owned or affiliated with an institution of higher education.
(6) The person has:
(A) demonstrated good faith business practices in previous efforts to
enforce the patent, or a substantially similar patent; or
(B) successfully enforced the patent, or a substantially similar patent,
through litigation.
(7) Any other factor the court finds relevant.

§ 4198. BOND
Upon motion by a target and a finding by the court that a target has
established a reasonable likelihood that a person has made a bad faith
assertion of patent infringement in violation of this chapter, the court shall
require the person to post a bond in an amount equal to a good faith estimate
of the target’s costs to litigate the claim and amounts reasonably likely to be
recovered under § 4199(b) of this chapter, conditioned upon payment of any
amounts finally determined to be due to the target. A hearing shall be held if
either party so requests. A bond ordered pursuant to this section shall not
exceed $250,000.00. The court may waive the bond requirement if it finds the
person has available assets equal to the amount of the proposed bond or for
other good cause shown.

(a) The Attorney General shall have the same authority under this chapter
to make rules, conduct civil investigations, bring civil actions, and enter into
assurances of discontinuance as provided under chapter 63 of this title. In an
action brought by the Attorney General under this chapter the court may
award or impose any relief available under chapter 63 of this title.
(b) A target of conduct involving assertions of patent infringement, or a
person aggrieved by a violation of this chapter or by a violation of rules
adopted under this chapter, may bring an action in Superior Court. A court
may award the following remedies to a plaintiff who prevails in an action
brought pursuant to this subsection:
(1) equitable relief;
(2) damages;
(3) costs and fees, including reasonable attorney’s fees; and
(4) exemplary damages in an amount equal to $50,000.00 or three times
the total of damages, costs, and fees, whichever is greater.
(c) This chapter shall not be construed to limit rights and remedies
available to the State of Vermont or to any person under any other law and
shall not alter or restrict the Attorney General’s authority under chapter 63 of
this title with regard to conduct involving assertions of patent infringement.

This act shall take effect on July 1, 2013.





Are Human Genes Patentable?—The Experts Weigh In

Pending Supreme Court Case Against Myriad Genetics Is Analyzed in Biotechnology Law Report

New Rochelle, NY, May 22, 2013—A landmark case for the biotechnology industry awaits a Supreme Court ruling, expected in June, on whether polynucleotides isolated from human genes should continue to be subject to patent protection. On April 15, each side in the so-called Myriad Genetics case presented an oral argument, during which the Supreme Court Justices, in their questions and comments, may have hinted at which way they lean. An insightful analysis of the issues, the legal briefs presented to the Court, and the oral arguments is presented in a set of articles published in Biotechnology Law Report, a publication of Mary Ann Liebert, Inc., publishers.

The two articles “After Myriad Oral Argument, Supreme Court Set to Decide Patentability of Isolated Human DNA Molecules,” authored by Marc Hearron, James Mullen III, and Matthew Kreeger, attorneys with Morrison & Foerster (Washington, D.C., San Diego, and San Francisco offices, respectively), and “The Supreme Court takes on the Patent Eligibility of Human Genes: AMP v. Myriad,” by Dalila Argaez Wendlandt and Joseph van Tassel, Ropes & Gray, Boston, MA, provide essential background to the issues in the Myriad Genetics case and help the reader prognosticate on the likely outcome of the case. The articles are available free on the Biotechnology Law Report website.

The defendant company has developed tests for the presence of the BRCA1 and BRCA2 gene variants and provides them, for significant fees, to help genetic counselors and physicians predict a patient’s risk of developing breast or ovarian cancer. Among the plaintiffs in the case is the Association for Molecular Pathology, whose members wish to compete with Myriad Genetics to offer testing for such genetic mutations.

Represented by Daniel Ravicher of the Public Patent Foundation, as well as attorneys with the American Civil Liberties Union, the plaintiffs seek to reshape previously applied principles of chemical patent law to invalidate all patents that claim isolated genes and methods of testing with them. They challenge the validity of those patents on the ground that human genes are “products of nature.” They say that this should not be considered patentable subject matter, even if the useful properties of the patented molecules hadn’t been appreciated before their discovery by the “inventors” named in the patents.

“Those who hope the court will rule adversely to the patentees are encouraged by last year’s Supreme Court decision in Mayo Collaborative Services v. Prometheus Labs. In that case, the Court said that a newly discovered ‘law of nature’ is not patentable and invalidated patents that had been granted to a Canadian hospital for a method of determining how to regulate dosage of a drug, based on measuring the concentration of drug metabolites,” states Gerry J. Elman, Editor-in-Chief of Biotechnology Law Report and President of Elman Technology Law (Media, PA). “But last week, in Bowman v. Monsanto, the Supreme Court showed that they are more willing to enforce biotechnology-related patents than some had surmised from the Mayo decision.” Keep watching Biotechnology Law Report after the June ruling in Myriad Genetics, for further analysis of its anticipated impact on the evolution of personalized medicine and other developments in biotechnology.

About the Journal
Biotechnology Law Report is an authoritative journal published bimonthly online with Open Access options and in print. First published in 1982, the Journal continues to lead the field in its coverage of the evolving body of law and government regulation concerning biotechnology. Focusing primarily on industries in which biotechnology underlies the rapid development of new products, including pharmaceuticals, chemicals, agriculture, food processing, energy, mineral recovery, and waste treatment, Biotechnology Law Report provides information and critical assessment of all legal aspects of these technologies as they move toward commercialization. Complete tables of content and a sample issue may be viewed on the Biotechnology Law Report website.

About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science, biomedical research, and law, including Election Law Journal, Gaming Law Review and Economics, and Environmental Justice. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s over 70 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

Spark Your Creativity: participate online in Tina Seelig’s MOOC via Stanford’s Venture Lab

Stanford Professor of Creativity, Tina Seelig

Stanford Professor Tina Seelig

A Crash Course on Creativity” will be led by Stanford University professor Tina Seelig, April 22-June 2, 2013. During the course, teams from around the world will participate online in exercises to spark inventions and other creative results.

Delivered via Stanford’s platform Venture-Lab, this course will springboard from her book inGenius. The course is offered WITHOUT CHARGE to everyone who chooses to participate in this MOOC.

Trained as a neuroscientist and sharing with Intellectual Ventures chief Nathan Myhrvold a love of the science of cooking, Seelig directs the Stanford Technology Ventures Program where she focuses on developing the next generation of entrepreneurial leaders.

I had the pleasure of hearing Prof. Seelig speak about this last Saturday at the STARS Volunteer Leadership Assembly on the Stanford campus.

Click here to see patents we’ve filed for various companies and inventors.
Sign up for free
Register here to receive email notifications of podcasts, blog posts and other informative material from Elman Technology Law. And join the annual mailing list for our calendar with images from historic patents.
Click Below & Use Social Media
Archive of Our Postings

Make a Payment
Elman Technology Law clients can quickly and securely make a payment using LawPay. Click on the LawPay box below.